General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Neuromyelitis optica spectrum disorder (NMOSD)
Last updated July 3, 2025
Status:
Concluded with an LOI
Manufacturer:
Takeda Canada Inc.
Indication:
For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.
Last updated July 2, 2025
Vemlidy (tenofovir alafenamide)
Status:
Concluded with an LOI
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Chronic Hepatitis B virus
Last updated June 30, 2025
TheraSphere Y-90 Glass Micropheres (Yttrium-90 microspheres)
Status:
Concluded with an LOI
Manufacturer:
Boston Scientific Corporation
Indication:
As selective internal radiation therapy (SIRT) for local tumor control of solitary tumors in patients with intermediate- or advanced-stage hepatocellular carcinoma (HCC), including those with recurrent or unresectable HCC. In addition to HCC
Last updated June 26, 2025
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
For the treatment of adult patients with primary advanced or recurrent endometrial carcinoma, in combination with carboplatin and paclitaxel and then continued as monotherapy.
Last updated June 24, 2025
Status:
Concluded without agreement
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated June 23, 2025
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Retinal vein occlusion
Last updated June 20, 2025
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
In combination with Venclexta, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Last updated June 17, 2025
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
In combination with Gazyva, for the treatment of patients with previously untreated chronic lymphocytic leukemia
Last updated June 17, 2025
Status:
Concluded with an LOI
Manufacturer:
Jamp Pharma Corporation
Indication:
Multiple Indications
Last updated June 17, 2025